Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


S-P/Santarus deal

This article was originally published in The Tan Sheet

Executive Summary

Santarus announces a $5 mil. milestone relating to progress on clinical product development for proton pump inhibitor products using the company's patented PPI technology has been achieved under its over-the-counter license agreement with Schering-Plough. Santarus expects to receive the milestone within 30 days, the firm states in a July 20 release. Santarus already received a $15 million upfront license fee in November and, upon the achievement of certain regulatory and sales milestones, may receive up to an additional $60 million in milestone payments. The companies hope the proton pump inhibitor will have an edge against Procter & Gamble's Prilosec OTC in the heartburn market ( 1"The Tan Sheet" Oct. 23, 2006, p. 3)...

You may also be interested in...

Zegerid May Bring Quick Heartburn Relief To Market Under Santarus/S-P deal

Immediate-release delivery will give Santarus' proton pump inhibitor Zegerid (omeprazole/sodium bicarbonate) an edge against Prilosec OTC in the heartburn market if the firm can pull off a planned Rx-to OTC switch

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts